Raises full-year 2026 revenue guidance to a range of $101-$105 million Significantly strengthens balance sheet Enters into exclusive U.S. distribution agreement for Dilon Technologies' HEMOBLAST ® Bellows product for high-performance hemostasis; hires Dilon's U.S.

BELGRADE, Mont., May 7, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc.   (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced that it will release its financial results for the first quarter ended March 31,

BELGRADE, Mont., May 6, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc.   (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced the commercial launch of Trivium™ Shaped, an extension of its Trivium™ bone graft

Xtant has hired Dilon's U.S. sales team to assist in selling the HEMOBLAST ® Bellows product and penetrating the estimated $2.0 billion global addressable market for hemostatic products BELGRADE, Mont. and NEWPORT NEWS, Va., April 13, 2026 /PRNewswire/ --  Xtant Medical Holdings, Inc.  (NYSE

BELGRADE, Mont., April 9, 2026 /PRNewswire/ --  Xtant Medical Holdings, Inc. (NYSE American: XTNT), in partnership with the Montana Governor's Office of Community Service (GOCS), today announced support for the Threshold of Life Memorial, a statewide initiative honoring organ, eye, and tissue

Full year 2025 revenue totals $133.9 million, an increase of 14% year-over-year Xtant delivers positive net income, adjusted EBITDA and operating cash flow Total cash of $17.3 million as of December 31, 2025 with an additional $10.5 million received subsequent to year end related to divestiture

BELGRADE, Mont., March 25, 2026 /PRNewswire/ --  Xtant Medical Holdings, Inc.  (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced that it will release its financial results for the fourth quarter and full

Xtant received $10.7 million in satisfaction of unsecured promissory note issued to Xtant by Companion Spine plus related working capital adjustments BELGRADE, Mont., March 2, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc.   (NYSE American: XTNT), a medical technology company focused on surgical

BELGRADE, Mont., Feb. 25, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc.  (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and wound care disorders, today announced that Sean Browne, CEO, Scott Neils, CFO, and Mark

nanOss Strata™ is designed to more closely mimic the structure of human bone, increase the graft's surface area, improve osteoconductivity and enhance the stimulation of cellular activity BELGRADE, Mont. , Dec. 11, 2025 /PRNewswire/ --  Xtant Medical Holdings, Inc.